Clinical Trial: Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title: Phase II Study of Cisplatin Plus Epirubicin Salvage Chemotherapy in Refractory Germ Cell Tumors

Brief Summary: This study proposes to evaluate the combination of cisplatin plus epirubicin in patients with refractory germ cell tumor not amendable to cure with surgery or standard platinum salvage chemotherapy. This regimen will be used in eligible patients after progression on ECOG Study E39897.

Detailed Summary: To determine the feasibility and toxicity of combining epirubicin to fixed does cisplatin; to determine the partial and complete response rate and duration of remission; to determine the toxicity; to ascertain the potential for greater than 12 month continuous disease-free survival and, therefore, potential curability.
Sponsor: Indiana University School of Medicine

Current Primary Outcome: To determine the feasibility and toxicity of combining epirubicin to fixed dose cisplatin

Original Primary Outcome: Same as current

Current Secondary Outcome: To determine the partial and complete response rate and duration of remission

Original Secondary Outcome: Same as current

Information By: Indiana University

Dates:
Date Received: September 8, 2005
Date Started: October 2000
Date Completion:
Last Updated: May 30, 2014
Last Verified: May 2014